REXAHN GETS EUROPEAN PATENT FOR ANXIETY DRUG

Rexahn, a clinical stage biopharmaceutical company, announced that a European patent (EP 1206261) has been granted for the treatment of behavioural diseases with its leading CNS drug candidate, RX-10100. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=35344§ionid=)